|
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
Jul 31, 2026 Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation Jul 30, 2026 Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD) Jul 30, 2026 Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? Jul 30, 2026 Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial Jul 30, 2026 Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL Jul 29, 2026 Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial Jul 29, 2026 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Jul 29, 2026 Rethinking Regulatory Protections for Accelerated Approvals With Supplementary Indications Jul 29, 2026 He Was Always There Jul 28, 2026 Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial Jul 27, 2026 SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer Jul 27, 2026 Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Jul 27, 2026 Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors Jul 27, 2026 Anti-TIGIT in PD-L1–High Advanced Non–Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward Jul 27, 2026 Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) Jul 27, 2026 |
He Was Always There Journal of Clinical Oncology, Volume 44, Issue 26, Page 2554-2556, September 2026. <br/> 2026-09-10T07:00:00Z Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study Journal of Clinical Oncology, Volume 44, Issue 26, Page 2529-2542, September 2026. <br/> 2026-09-10T07:00:00Z Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Journal of Clinical Oncology, Volume 44, Issue 26, Page 2507-2516, September 2026. <br/> 2026-09-10T07:00:00Z COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma Journal of Clinical Oncology, Volume 44, Issue 26, Page 2490-2495, September 2026. <br/> 2026-09-10T07:00:00Z Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Journal of Clinical Oncology, Volume 44, Issue 26, Page 2543-2553, September 2026. <br/> 2026-09-10T07:00:00Z Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer Journal of Clinical Oncology, Volume 44, Issue 26, Page 2496-2506, September 2026. <br/> 2026-09-10T07:00:00Z Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study Journal of Clinical Oncology, Volume 44, Issue 26, Page 2517-2528, September 2026. <br/> 2026-09-10T07:00:00Z Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2 Journal of Clinical Oncology, Volume 44, Issue 26, Page e127-e139, September 2026. <br/> 2026-09-10T07:00:00Z Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study Journal of Clinical Oncology, Volume 44, Issue 26, Page 2482-2489, September 2026. <br/> 2026-09-10T07:00:00Z Oncology Drug Development: Challenges of Increasingly Available Therapies Journal of Clinical Oncology, Volume 44, Issue 26, Page 2471-2475, September 2026. <br/> 2026-09-10T07:00:00Z Sustaining High Reliability Amid Artificial Intelligence Adoption in Oncology Journal of Clinical Oncology, Volume 44, Issue 26, Page 2476-2481, September 2026. <br/> 2026-09-10T07:00:00Z Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers Journal of Clinical Oncology, Volume 44, Issue 26, Page 2560-2561, September 2026. <br/> 2026-09-10T07:00:00Z Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy Journal of Clinical Oncology, Volume 44, Issue 26, Page 2557-2558, September 2026. <br/> 2026-09-10T07:00:00Z Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials Journal of Clinical Oncology, Volume 44, Issue 26, Page 2563-2563, September 2026. <br/> 2026-09-10T07:00:00Z Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions Journal of Clinical Oncology, Volume 44, Issue 26, Page 2563-2564, September 2026. <br/> 2026-09-10T07:00:00Z Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy Journal of Clinical Oncology, Volume 44, Issue 26, Page 2558-2560, September 2026. <br/> 2026-09-10T07:00:00Z |
The Long Shadow of Bedlam
A dying patient in a state psychiatric hospital has no access to a DNR order that would make the process as peaceful as possible — as the notorious Bedlam casts a shadow over mental health care to this day. 2026-09-05
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients had a response. 2026-09-03
Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. 2026-09-03
Pulmonary Nodules This review summarizes the management of pulmonary nodules, with an emphasis on nodule type, imaging follow-up, cancer risk, and strategies to balance timely diagnosis with avoidance of unnecessary procedures. 2026-09-03
Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML I first treated a patient with leukemia with the so-called “7+3” regimen (a 7-day continuous infusion of cytarabine plus three daily infusions of an anthracycline, usually daunorubicin)1 more than 50 years ago during my residency. To be candid, I had little understanding of what I was doing but... 2026-09-03
Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. 2026-09-03
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. 2026-08-20
Myeloproliferative Neoplasms This review summarizes the pathogenesis and treatment of myeloproliferative neoplasms, highlighting the role of driver mutations, inflammation, and emerging targeted therapies that may achieve durable disease modification. 2026-08-20
Marijuana Rescheduling — A Game Changer for Research? A proposed reclassification of medical marijuana products as Schedule III drugs would address only two of the three key barriers to research on marijuana’s safety and effectiveness for various indications. 2026-08-20
Severe Plasmodium falciparum Malaria An 82-year-old man was brought to the ED after being “found down.” One week earlier, he had returned from a 1-month visit to Chad. A peripheral-blood smear showed ring-form trophozoites within erythrocytes. 2026-08-20
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. 2026-08-13
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. 2026-08-13
Warthin Tumors A 55-year-old man with a smoking history of 10 pack-years presented with 2 years of an enlarging, painless lump below his right ear. A previously unnoticed smaller mass in the left parotid gland was seen on examination. 2026-08-13
Disseminated Fusariosis A 61-year-old man with prolonged neutropenia after chemotherapy for AML was evaluated for persistent fever despite antimicrobial therapy. Physical examination was notable for a skin macule with central necrosis on the chest. 2026-08-13
PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma In a child with advanced nephroblastoma, T-cell therapy targeting preferentially expressed antigen in melanoma led to a 69% tumor reduction, with molecular, metabolic, and histologic evidence of complete remission at 200 days. 2026-08-13
Perioperative Apalutamide in High-Risk Localized Prostate Cancer In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. 2026-08-06
A Watershed Moment in the Perioperative Treatment of Prostate Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... 2026-08-06
Consumed with Inflammation A 60-year-old woman with stage II triple-negative breast cancer presented to the ED with a weeklong history of fevers, rigors, malaise, nonproductive cough, and nausea. 2026-08-06
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. 2026-07-30
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. 2026-07-30
|
|
|
| |||
|
[Editorial] Beyond cancer: The Right to be Forgotten
In Germany, politicians are pressing the government to end discrimination against people in remission from cancer. Germany remains among the European outliers in obstructing a fresh start for former patients. A petition campaigning under the slogan, “Healed. And Yet Disadvantaged”, has gathered over 56 000 signatures. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer The adoption of total mesorectal excision (TME) has significantly reduced the risk of locoregional recurrence in patients with rectal cancer. However, this reduction comes at the cost of substantial treatment-related morbidity, including permanent stoma formation and long-term impairment of bowel, urinary, and sexual function that adversely impact quality of life (QOL) and functionality.1 As such, management has evolved toward risk-adapted, patient-centred strategies, including selective organ preservation that is oncologically safe and associated with better QOL. Sun, 23 Aug 2026 22:30:02 +0000
[Comment] Radiotherapy dose intensification for high-risk prostate cancer—what is gained? Can a modest increase in radiotherapy dose make a difference for a patient with high-risk prostate cancer? In The Lancet Oncology, Christophe Hennequin and colleagues present results from the GETUG-AFU 18 trial,1 which enrolled 505 patients across 25 centres in France to answer this important and relevant question. Participants were randomly assigned (1:1) to receive 70 Gy or 80 Gy to the prostate, along with 3 years of androgen deprivation therapy (ADT). The higher radiotherapy dose improved biochemical or clinical progression-free survival (the primary outcome) from 88·1% to 91·4% at 5 years and from 72·2% to 83·6% at 10 years (stratified hazard ratio 0·56, 95% CI 0·40–0·78). Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Beyond visual tumour-infiltrating lymphocytes assessment Stromal tumour-infiltrating lymphocytes (sTILs) have become one of the most clinically informative immune biomarkers in breast cancer,1 associated with improved response to systemic therapy and favourable long-term outcomes.2,3 Reproducibility is not the obstacle to their use. In a secondary analysis of the APHINITY trial in The Lancet Oncology, Luis E Lara González and colleagues4 found a high interobserver reproducibility among five pathologists scoring 262 cases to international guidelines.5 However, scoring requires expert pathologists, quality-assured haematoxylin and eosin slides, and time, which are unevenly distributed across health systems. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Afghan women's cancer crisis deserves its own response Non-communicable diseases (NCDs) already account for an estimated 43% of all deaths in Afghanistan1 and are projected to exceed 60% by 2030, mainly among women. However, access to cancer care remains critically limited—Afghanistan has only two functioning cancer treatment centres, both in Kabul (Jamhuriat Hospital and the newly opened National Cancer Diagnosis and Treatment Hospital), for more than 40 million people, and neither offers radiotherapy.2 These gaps contribute to delayed diagnosis, poor outcomes, and avoidable mortality, and highlight the urgent need to strengthen cancer prevention, detection, and treatment nationwide. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Cancer care in Canada Canada's cancer care system has achieved substantial progress through advances in cancer prevention, screening, early detection, and treatment, including targeted therapies and immunotherapy.1 Although both the age-standardised incidence rate and age-standardised mortality rate (ASMR) continue to decline, an estimated 254 100 Canadians will be diagnosed with cancer and an estimated 87 900 will die from the disease in 2026.2 Tue, 01 Sep 2026 00:00:00 -0700
[Correspondence] Closing the gap in southeast Asia's diagnostic molecular oncology testing We welcome The Lancet Oncology Commission highlighting the global cancer workforce crisis, which projects a shortage of 9·47 million diagnostic (pathology and imaging) specialists in Asia by 2050 and identifies pathologists as yielding the highest return on investment in the region (US$35·4 per $1 invested).1 Although the Commission focuses primarily on Africa and Latin America, southeast Asia offers a compelling example of how diagnostic workforce shortages and limited laboratory capacity directly constrain access to precision oncology. Tue, 01 Sep 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 686–98 Brunt AM, Cafferty FH, Kirby AM, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy. Lancet Oncol 2026; 27: 686–98—The appendix of this Article has been corrected as of Aug 24, 2026. Tue, 01 Sep 2026 00:00:00 -0700
[News] UK study to report cancer risk in armed services personnel The UK Government has announced it is to conduct a study into cancer risk in armed services personnel, both past and present. The UK's Ministry of Defence says the study is part of its efforts to improve the long-term health of those who serve and have served in the armed services. The UK-wide epidemiological study (covering all four nations) will examine cancer incidence among those who have served since 1990, including some 1·4 million currently serving and veterans. No personnel will need to take action to be included in the study, as it will use existing records held in by the country's National Health Service (NHS). Thu, 23 Jul 2026 22:30:01 +0000
[News] Sweden plans to restrict PFAS On July 23, 2026, the Government of Sweden announced plans to prohibit perfluoroalkyl and polyfluoroalkyl substances (PFAS), also called forever chemicals, in certain consumer products such as clothing, footwear, cosmetics, and kitchen utensils starting Jan 1, 2028. This plan will make Sweden one of the latest European countries to propose national restrictions ahead of the broader EU legislation. Thu, 30 Jul 2026 22:30:02 +0000
[News] CARICOM moves towards regional framework for cancer The Caribbean Community (CARICOM) is moving towards a regional framework for cancer care after calling for stronger cooperation between members, although questions remain over funding, governance, and implementation. The call followed the 14th Annual Caribbean Association for Oncology and Hematology (CAOH) Scientific Conference, held in Trinidad and Tobago, on July 17–19, 2026. Thu, 30 Jul 2026 22:30:02 +0000
[News] UK–Japan research collaboration for cancers in children and young people On July 28, 2026, organisations from the UK and Japan announced a partnership that will provide funding opportunities for international collaborative clinical trials aimed at developing innovative treatments for cancers affecting children and young people (CYP). Thu, 06 Aug 2026 22:30:02 +0000
[News] 2030 hepatitis elimination targets might be missed in Europe Europe is set to miss the WHO target to eliminate viral hepatitis as a public health threat by 2030 despite progress in screening because of gaps in vaccination and reaching key populations, according to the European Centre for Disease Prevention and Control (ECDC). Thu, 06 Aug 2026 22:30:02 +0000
[News] New liver cancer medicine fast-tracked by UK Government A new medicine for hepatocellular liver cancer has been granted an Innovation Passport through the UK's Innovative Licensing and Access Pathway (ILAP), the Medicines and Healthcare products Regulatory Agency (MHRA) announced last week. Thu, 13 Aug 2026 22:30:01 +0000
[News] Saint Lucia launches national cancer registry The eastern Caribbean island nation of Saint Lucia has launched a national population-based cancer registry, 7 years after first announcing plans to establish one, as it seeks to replace fragmented records and modelled estimates with systematic data on cancer incidence. The registry comes as the country develops a cancer control plan, but its usefulness will depend on complete case reporting, specialist staff, sustained financing, and whether the resulting data influence policy making. Thu, 13 Aug 2026 22:30:02 +0000
[Perspectives] A polycrisis in cancer care: Cuba's system under the oil blockade Cuba's cancer care programme is facing a polycrisis, in which disruptions in energy supply, pharmaceutical access, and technological capacity interact and reinforce one another. The strain is most visible at two of its most resource-intensive nodes: the supply of cytostatic drugs for chemotherapy and the operational readiness of radiotherapy. Both have long been limited by restricted access to pharmaceutical markets, equipment, and spare parts under the decades-long US trade embargo. The oil blockade imposed on Jan 29, 2026 (figure 1), has converted these chronic constraints into an acute systemic breakdown. Fri, 19 Jun 2026 22:30:01 +0000
[Perspectives] Rethinking failure and tolerance in oncology When I received my first chemotherapy tablets, the literature was terrifying: the insert warned against touching the pills or my bodily fluids without gloves. The bag read CAUTION next to a neon yellow biohazard symbol. Shared bathrooms were discouraged. I thought: if this treatment is so dangerous, why am I supposed to ingest it? Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement versus TACE. These findings support a STRIDE-based regimen as a potential new treatment option for people with embolisation-eligible HCC; additional follow-up is being conducted for final analysis of overall survival across treatment groups. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial Ivonescimab plus chemotherapy showed a clinically meaningful and statistically significant progression-free survival benefit in patients with EGFR-mutated NSCLC after progression on EGFR-TKI therapy. The clinical benefit and lack of new safety signals of ivonescimab with chemotherapy support the potential for the combination as a new treatment option in this patient population. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial For patients with resected ALK-positive NSCLC, adjuvant alectinib had a manageable safety profile; HRQoL improved and was maintained over 2 years of active treatment. Together with the disease-free survival benefit seen in ALINA, these data support adjuvant alectinib as an important new standard-of-care for patients with resected ALK-positive NSCLC. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial These early results support a response-adapted organ-preservation approach, with LCCRT appearing more effective than SCRT at 12 months. Organ-preservation might also reduce treatment-related toxicity compared with primary TME. Longer follow-up is needed for the prespecified 30-month endpoint and definitive functional and oncological outcomes. Sun, 23 Aug 2026 22:30:02 +0000
[Articles] Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial The combination of ifebemtinib and garsorasib showed promising anticancer activity and manageable safety profile in previously treated patients with KRASG12C-mutated metastatic colorectal cancer. Although the improvement in response rate did not reach statistical significance in the randomised study, these findings support further evaluation of ifebemtinib plus garsorasib in this population. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial SHR-A2102 demonstrated a safety profile consistent with its topoisomerase I inhibitor payload and showed promising activity in patients with various advanced solid tumours who had previously received anti-cancer treatment. A range of active dose was identified in various tumour types. Several trials are ongoing to evaluate SHR-A2102, either as monotherapy or in combination, in advanced solid tumours. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial For patients with high-risk prostate cancer, radiotherapy at a total dose of 80 Gy, in combination with long-term ADT, improved progression-free survival and could be a potential option in this situation. However, given the low number of events, further research is needed to consolidate and confirm the benefit in dose-escalation in prostate cancer-specific survival and overall survival. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial Standardised manual sTIL scoring was reproducible, and digital and AI-based methods showed consistent prognostic stratification and potential for treatment-benefit stratification despite only modest correlation between platforms. AI spatial metrics provided complementary information beyond sTIL density and could support more scalable immune assessment. Future studies are needed to validate these approaches in independent cohorts and to clarify their clinical utility for stratifying contemporary HER2-directed therapies. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study Two cTIL models deployed entirely without retraining or modification provided statistically significant prognostic information and improved risk discrimination compared with clinicopathological variables alone in this large, platform-based, independent validation study. Although cTIL score did not incrementally improve prognostication compared with models combining clinicopathological variables with sTIL score, these findings support the application of cTILs as a reproducible prognostic biomarker, particularly in settings where routine or widespread pathologist assessment is unavailable. Tue, 01 Sep 2026 00:00:00 -0700
[Policy Review] Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient selection and local treatment strategies. This project, endorsed by US and European surgical and radiation oncology societies, aimed to gather expert consensus on these issues. A questionnaire on second iBCE local treatment was developed and reviewed by a core group of eight experts, and Delphi methodology was applied over two rounds to 36 panellists, including radiation oncologists, breast surgeons, a plastic surgeon, and medical physicists. Wed, 29 Jul 2026 22:30:02 +0000
[Review] Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group Tumour-infiltrating lymphocytes (TILs) are prognostic and predictive biomarkers in breast cancer. High pre-treatment TILs are associated with a favourable prognosis and improved response to systemic therapies. However, the role of TILs in mediating response to radiotherapy in breast cancer remains underexplored, with scarce clinical evidence to date. In this Review, we present an overview of current evidence and potential mechanisms, highlight opportunities for integrating TILs into radiation oncology trials and clinical practice, and call for standardised TIL reporting to accelerate biomarker-driven individualisation of radiotherapy in breast cancer. Tue, 01 Sep 2026 00:00:00 -0700
[Personal View] Challenges in the use of the European Society for Radiotherapy and Oncology–European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer The oligometastatic disease classification system, developed within the European Society for Radiotherapy and Oncology (ESTRO)–European Organisation for Research and Treatment of Cancer (EORTC) OligoCare project, has been proposed for prognostic stratification and clinical trial design across solid tumours. Its application to ovarian cancer, however, is challenged by two disease-specific features: early and often diffuse peritoneal spread and the difficulty of lesion enumeration when peritoneal deposits are not discretely measurable. Tue, 01 Sep 2026 00:00:00 -0700
|
Long‐term outcomes and patterns of failure in patients with thymic malignancies treated with surgery and radiation therapy
In patients with surgically treated thymic malignancies, tumor invasiveness, especially vascular invasion, was the strongest predictor of recurrence and should guide risk stratification. Failure was predominantly pleural, with rare in‐field recurrence, indicating good local control but a need for better strategies against pleural relapse. Survival benefit from peri‐operative radiation remains uncertain and should be tested prospectively. Thu, 03 Sep 2026 11:12:29 -0700 Issue Information Thu, 03 Sep 2026 11:11:44 -0700 |
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
This randomized clinical trial examines the efficacy, safety, and patient-reported outcomes of adding serplulimab to chemotherapy for patients with extensive-stage small cell lung cancer. Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis This systematic review and meta-analysis estimates the frequency of reported second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy and evaluates whether study-level characteristics and reporting definitions influence observed estimates. Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial This nonrandomized clinical trial evaluates the efficacy and tolerance of single-fraction stereotactic body radiotherapy in men with localized prostate cancer. Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors This cohort study explores the long-term outcomes of patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial This randomized clinical trial evaluates the efficacy and safety of fovinaciclib plus an aromatase inhibitor as first-line treatment for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical Trial This nonrandomized clinical trial aims to determine the efficacy and toxicity profile of a reduced preoperative radiotherapy dose in patients with myxoid liposarcoma. Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial This secondary analysis of a randomized clinical trial evaluates 5-year outcomes and characterizes circulating tumor DNA dynamics in patients with Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening. Hypernatremia and Polyuria in a Patient With Metastatic Breast Cancer A 58-year-old woman with breast cancer with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen, while no discrete sellar or suprasellar masses were noted. What is your diagnosis? Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer Durable Gains and Persistent Questions From the ASTRUM-005 Trial Georgia O’Keeffe, Hannah Wilke, and Choosing One’s Own Narrative—Sovereignty This essay explores how cancer is depicted in the work of Georgia O’Keeffe and Hannah Wilke. Three-Body Problem at Digital Frontiers This essay discusses the authors’ experience with and lessons learned from their hospital’s telemedicine-based service for managing low-risk acute lymphoblastic leukemia in children who have achieved complete remission. One Ovary Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply Survival in the SONIA Trial Survival in the SONIA Trial Survival in the SONIA Trial—Reply Notice of Retraction: Lei Z. Rethinking End Points in Modern Oncology Trials—Beyond the P Value. JAMA Oncol. 2025;11(12):1553-1554. Error in Open Access License JAMA Oncology |
|
|
| |||
|
[Editorial] Beyond maximum grade: a decade in the making
The past decade has seen many advances in the treatment of haematological malignancies, particularly with the rise of immunotherapies and CAR T-cell therapies. Other treatments, such as tyrosine kinase inhibitors for chronic myeloid leukaemia, have changed the disease to that of a chronic condition, treated with continuously administered therapies that have unique adverse events over time. With these changes, how adverse events are measured, reported, and the patient's perception of these adverse effects needs to be updated as well. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Beyond maximum grade: making toxicity count In modern haematology, toxicities often persist long after completion of treatment regimens. Advances in overall survival, alongside the expanded adoption of continuous dosing regimens, immunotherapies, and cellular therapies, have rendered adverse events a lasting burden for patients throughout remission, chronic disease management, and long-term survivorship. Yet the standard Common Terminology Criteria for Adverse Events (CTCAE) maximum grade only records toxicity at its worst point, rather than its persistence, recurrence, cumulative burden, or short-term or long-term effects on daily life. Tue, 01 Sep 2026 00:00:00 -0700
[Correspondence] FAIR(er) treatment of non-anaemic iron deficiency during pregnancy: clarifying the evidence – Authors' reply We thank Ankur Jain for their thoughtful comments regarding our FAIR trial1 and the discussion regarding the prevention of anaemia during pregnancy.2 Our findings show that, among women with non-anaemic iron deficiency diagnosed at the first antenatal care visit, intravenous iron was superior to 30 mg daily oral iron in preventing maternal anaemia. We take the opportunity to address the points raised in the Correspondence. Tue, 01 Sep 2026 00:00:00 -0700
[News] ISTH 2026 Congress Dr Steven McKenzie (Cardeza Foundation for Hematologic Research, Philadelphia, PA, USA) and colleagues presented the ALATHEA trial (NCT05785819) that compared the safety and efficacy of 200 mg intravenous VLX-1005 every 12 h (a small-molecule inhibitor of 12-lipoxygenase) versus placebo in patients with suspected heparin-induced thrombocytopenia undergoing standard-of-care treatment with a direct thrombin inhibitor. 24 patients were randomised 1:1 to the two treatment groups; 22 received study treatment and 17 had confirmed HIT (eight received VLX-1005 and nine placebo). Tue, 01 Sep 2026 00:00:00 -0700
[News] Building stronger blood systems On June 12, 2026, WHO released its latest global report on blood safety and availability, drawing on data from 168 countries. Voluntary unpaid donors now account for 85% of blood donations. Total blood collections increased by 19% from 2013 to 2023 across 132 countries. Nonetheless, governance and oversight remain patchy. 48 countries do not have specific legislation addressing the safety and quality of blood and blood products for transfusion, while 62 countries have not established systems for regular inspection of blood transfusion services. Tue, 01 Sep 2026 00:00:00 -0700
[In Focus] Menstruation in Nepal: tradition, stigma, and transition Nepal, a landlocked country in south Asia bordered by China and India, is known for its geographical, cultural, and religious diversity. It is the only country with a living goddess—The Kumari—a chosen pre-menarcheal girl from Newar community worshipped by all Nepalis, including the head of state. But among this diversity is the belief around menstruation (although differing between region, cast, and culture) that leads to nearly 89% of Hindu women and girls in Nepal to experience some form of menstrual restriction. Mon, 13 Jul 2026 02:30:03 +0000
[In Focus] Reproductive health in Ireland: moving forward as others roll back When politics and reproductive health intersect, women, girls, and people with the potential to menstruate can be substantially impacted, as seen recently in the USA. The devastating effects of undermining and defunding women's health programmes have generated worthy media attention; however, progress in reproductive health is less fêted. As an example, Ireland has emerged as a progressive voice for women's health despite the persistence into the 21st century of highly restrictive, conservative legislation shaped by historical religious influences on society. Mon, 13 Jul 2026 02:30:02 +0000
[In Focus] Living with a bleeding disorder as a woman I was remembering all the times I wanted to talk to my dad to ask him about what was happening to me, but he avoided it every time. He did not want to accept that I also needed special medical care. It hurt me a lot to see my dad suffering because of haemophilia, but it hurt me even more not to feel accepted or seen by him. Mon, 13 Jul 2026 02:30:02 +0000
[Articles] Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial Epcoritamab plus rituximab–lenalidomide showed high activity in first-line treatment for follicular lymphoma, with 95% of patients having a response over 3 years of follow-up, supporting this treatment regimen as a promising approach that warrants further analysis to ascertain its role in this setting. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial The addition of venetoclax to DA-EPOCH-R resulted in excess mortality, prompting early study closure. Robust accrual shows that prospective multicentre trials are feasible in double-hit lymphoma, and the outcomes in the DA-EPOCH-R group serve as a benchmark for future studies. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party We showed that allo-HSCT is an effective and potentially curative treatment option for patients with hepatosplenic T-cell lymphoma; auto-HSCT is frequently followed by relapse and might be only recommended to patients with a complete response and ineligible for allo-HSCT. Thu, 13 Aug 2026 22:30:02 +0000
[Articles] CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study The results of this study showed the feasibility of rapid multicentre decentralised manufacturing and delivery of fresh CAR T-cell therapy in heavily pretreated B-cell non-Hodgkin lymphoma. The phase 2 part of ATALANTA-1 will provide further information on clinical activity and safety. Tue, 01 Sep 2026 00:00:00 -0700
[Series] Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies With more potent and novel treatment options, the number of survivors of haematological malignancies is increasing steadily, which in turn leads to the need for parallel improvements in survivorship monitoring and care. The present paper forms part of The Lancet Haematology Series on adverse event reporting, dedicated to improving adverse event assessment in haematological malignancies. Here, we review current survivorship care practice from a global perspective and conclude that access to long-term care plans is highly heterogeneous, with insufficient adaptation to the specific needs of haematological malignancy survivors treated curatively or non-curatively. Tue, 01 Sep 2026 00:00:00 -0700
[Series] Beyond maximum grade: key regulatory considerations in adverse event reporting The therapeutic landscape of haematological malignancies has evolved rapidly with the introduction of targeted therapies, immunotherapies, and cell-based and gene-based interventions, leading to improved survival and, in some cases, long-term remission or cure. These advances have exposed limitations in traditional approaches to adverse event assessment and reporting. Building on the 2025 Lancet Haematology Series on adverse event reporting, this Series paper examines how proposed improvements in toxicity reporting can be operationalised and integrated into regulatory decision making across clinical trials and real-world settings. Tue, 01 Sep 2026 00:00:00 -0700
[Series] Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers Real-world data are essential for understanding treatment-related toxicities in haematology, but traditional analyses are limited by data access, sharing constraints, and reduced data granularity. Emerging digital health technologies (DHTs), such as electronic patient-reported outcomes and wearable devices, can be used to capture continuous, patient-generated data not reliably captured by current post-marketing toxicity assessments. Artificial intelligence, synthetic data, and digital twins can be used to predict and simulate toxicity at a much larger scale beyond the capacity of traditional methodologies. Tue, 01 Sep 2026 00:00:00 -0700
[Clinical Picture] Concurrent BCR::ABL1 and CBFA2T3::GLIS2 fusions in an adult patient with acute leukaemia A 34-year-old man was admitted to Ruijin Hospital (Shanghai, China) in December, 2024, with acute onset of unexplained high fever and a 1-year history of mild splenomegaly. Laboratory testing showed rapidly progressive leukocytosis with 36% circulating blasts and thrombocytopenia. Abdominal ultrasonography verified splenomegaly, with the spleen measuring 156 mm in length and 58 mm in thickness. Tue, 01 Sep 2026 00:00:00 -0700
|
GPRC5D CAR-T: a new path beyond BCMA
Volume 148, Issue 10 September 3 2026 A CAR against rejection: dual-targeting allogeneic T cells Volume 148, Issue 10 September 3 2026 When chemotherapy interferes with the bone marrow niche Volume 148, Issue 10 September 3 2026 The hidden role of neutrophils in steroid-resistant GVHD Volume 148, Issue 10 September 3 2026 IL-16 drives a novel pathway of BTK inhibitor resistance Volume 148, Issue 10 September 3 2026 The hidden cost of RNA editing in megakaryopoiesis Volume 148, Issue 10 September 3 2026 Precision transfusion medicine in the omics era In this Perspective, D’Alessandro focuses on the future of transfusion medicine and how the new technologies of artificial intelligence and high-throughput genomics, proteomics, and metabolomics are expected to enhance management of the blood supply and donor selection as well as delivery of precision transfusion care to patients.
Volume 148, Issue 10 September 3 2026 Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma Once multiple lines of therapy, including B-cell maturation antigen (BCMA)–targeted agents, have failed, the prognosis for a patient with multiple myeloma remains bleak. Bal and colleagues report the results of a first-in-human study evaluating arlocabtagene autoleucel (arlo-cel), a G protein–coupled receptor family C group 5 member D (GPRC5D)–targeted chimeric antigen receptor (CAR) T-cell therapy, in 84 patients with heavily pretreated relapsed/refractory multiple myeloma. They observed stringent complete responses in 42% of patients, with an 18-month median duration of response, while low-grade cytokine release syndrome, high-grade cytopenias, and on-target skin and nail changes were common. Registrational trials are in progress.
Volume 148, Issue 10 September 3 2026 A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study Allogeneic chimeric antigen receptor (CAR) T cells have attraction as off-the-shelf products, but immunological barriers have limited persistence. To overcome the major barrier of host-versus-graft rejection, Jin et al developed multiplexed CRISPR/Cas9-edited anti–B-cell maturation antigen (BCMA) CAR T-cells that also target NKG2A, an inhibitory receptor expressed by activated natural killer (NK) cells, while incorporating knockout of genes required for graft-versus-host disease. In a small phase 1 study in relapsed and refractory multiple myeloma, they provide the first clinical evidence that directly targeting host NK cells can enhance CAR T-cell persistence after expansion in responding patients.
Volume 148, Issue 10 September 3 2026 Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration The signaling pathways that govern bone marrow (BM) niche function are beginning to be better elucidated. Uemura et al used murine models to show that the transcriptional regulators YAP and TAZ enable injury sensing by BM niche cells and play a role in restoring their structure and function. This promotes hematopoietic regeneration. Pharmacological activation of YAP/TAZ protects the BM niche and accelerates hematopoietic recovery after myelosuppressive therapies.
Volume 148, Issue 10 September 3 2026 IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy The interdependence of hematopoietic stem cells and the bone marrow (BM) stromal niche is central to normal blood cell production. Using murine models and patient samples, Li et al demonstrate that commonly used chemotherapy induces persistent remodeling of the BM niche, linking vascular and stromal damage to interferon gamma (IFN-γ)–producing CD8+ T cells and revealing that the recovery of blood counts does not reflect full microenvironmental repair. Their data suggest that strategies for BM niche repair warrant clinical development.
Volume 148, Issue 10 September 3 2026 Retinoic acid–driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD Gastrointestinal graft-versus-host disease (GI-GVHD) is a feared complication of allogeneic hematopoietic stem cell transplantation, and neutrophils are known to contribute to its severity. Liang et al identified a subset population of neutrophils expressing CD177 that is expanded selectively in the blood of pediatric patients with GI-GVHD and, in a murine model, elucidated how these cells drive steroid-resistant GVHD. They also describe how blocking retinoic acid signaling alleviates severity in the murine model. Further work is needed, but these data provide attractive clues for future clinical exploration.
Volume 148, Issue 10 September 3 2026 IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas Through exploration of resistance to Bruton tyrosine kinase (BTK) inhibitors in lymphomas, Arribas and colleagues discovered a novel mechanism mediated by the increased production of interleukin-16 (IL-16) that triggers autocrine and paracrine activation of CD9 and the downstream activation of phosphatidylinositol 3-kinase and MAPK signaling pathways. They show that targeting the IL-16/CD9 axis restores sensitivity to both BTK inhibitors and R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine [Oncovin], and prednisone) across multiple lymphoma models, including patient samples, suggesting a potential therapeutic strategy to overcome treatment resistance in refractory B-cell malignancies.
Volume 148, Issue 10 September 3 2026 Targeting PRMT9 overcomes venetoclax resistance in AML by modulating splicing and inhibiting translation Volume 148, Issue 10 September 3 2026 GLUL facilitates thrombocytopoiesis by restricting ammonia accumulation during megakaryocyte maturation Polyploidization is fundamental to megakaryocyte (MK) maturation but generates large amounts of endogenous double-stranded RNA (dsRNA), which requires editing to avoid immunogenicity. Chen and colleagues identified ammonia detoxification as an unexpected metabolic checkpoint of MK maturation, revealing that glutamine synthetase (GLUL) protects thrombopoiesis from the toxic ammonia released as a by-product of dsRNA editing. Genetic deletion or pharmacological inhibition of GLUL impairs MK maturation, reduces platelet production, shortens platelet survival, and delays platelet recovery after thrombocytopenia.
Volume 148, Issue 10 September 3 2026 Antifibrinolytic strategies improve liver regeneration in mice and reduce posthepatectomy liver failure in patients Volume 148, Issue 10 September 3 2026 Classic Hodgkin lymphoma showing interfollicular and intrasinusoidal involvement Volume 148, Issue 10 September 3 2026 |
Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T‐Cell Therapy
Thu, 03 Sep 2026 22:10:33 -0700 Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma Thu, 03 Sep 2026 06:11:42 -0700 Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment? Thu, 03 Sep 2026 06:11:42 -0700 Issue Information Thu, 03 Sep 2026 06:11:42 -0700 Correction to “Impairment of Innate Immunity and Depletion of Vaccine‐Induced Memory B and T Cells in the Absence of the Spleen” Thu, 03 Sep 2026 06:11:42 -0700 Monoclonal Gammopathy of Thrombotic Significance Thu, 03 Sep 2026 06:11:42 -0700 Unique Aspects of Allogeneic Hematopoietic Stem Cell Transplantation in VEXAS Syndrome: One Size Does Not Fit All Thu, 03 Sep 2026 06:11:42 -0700 Undetectable Hydroxyurea in an Untimed Blood Sample Does Not Establish Nonadherence Thu, 03 Sep 2026 06:11:42 -0700 A New Fetal Hemoglobin‐Related Phenotype in Sickle Cell Anemia Thu, 03 Sep 2026 06:11:42 -0700 Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta‐Thalassemia Trait Thu, 03 Sep 2026 06:11:42 -0700 Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count Thu, 03 Sep 2026 06:11:42 -0700 The Pitfalls of Categorizing Donor Age: Arbitrary Cutoffs Fail to Predict Survival in Haploidentical HCT Thu, 03 Sep 2026 06:11:42 -0700 Real‐Life Study on Gilteritinib‐Related Infections (GilteRInf): An Italian SEIFEM Study Thu, 03 Sep 2026 06:11:42 -0700 A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST) Thu, 03 Sep 2026 06:11:42 -0700 HLA‐Haploidentical Anti‐CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant‐Naïve Patients With Refractory T‐Cell Acute Lymphoblastic Leukemia Thu, 03 Sep 2026 06:11:42 -0700 Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Thu, 03 Sep 2026 06:11:42 -0700 Targeted Next‐Generation Sequencing of JAK2, CALR, and MPL in 10 326 Patients With Suspected Myeloproliferative Neoplasm Thu, 03 Sep 2026 06:11:42 -0700 Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations Thu, 03 Sep 2026 06:11:42 -0700 Acute Myeloid Leukemia Subtype‐Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy Thu, 03 Sep 2026 06:11:42 -0700 Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia Thu, 03 Sep 2026 06:11:42 -0700 Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study Thu, 03 Sep 2026 06:11:42 -0700 |
|
|
| |||
|
Long-term lessons from CALGB 10403 August 25 2026 - Volume 10, Issue 16 Linking hemostasis to bone health in bleeding disorders August 25 2026 - Volume 10, Issue 16 FLT3-ITD MRD is here to stay August 25 2026 - Volume 10, Issue 16 An ironclad case for cost-effective screening in pregnancy August 25 2026 - Volume 10, Issue 16 Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia August 25 2026 - Volume 10, Issue 16 Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation August 25 2026 - Volume 10, Issue 16 WT1 peptide vaccines of post–allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study August 25 2026 - Volume 10, Issue 16 Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial August 25 2026 - Volume 10, Issue 16 Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS August 25 2026 - Volume 10, Issue 16 Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD–mutated acute myeloid leukemia August 25 2026 - Volume 10, Issue 16 Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs August 25 2026 - Volume 10, Issue 16 Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma August 25 2026 - Volume 10, Issue 16 In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion August 25 2026 - Volume 10, Issue 16 Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab August 25 2026 - Volume 10, Issue 16 Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia–derived large oncosomes August 25 2026 - Volume 10, Issue 16 Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen August 25 2026 - Volume 10, Issue 16 High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT August 25 2026 - Volume 10, Issue 16 A PBD dimer–containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease August 25 2026 - Volume 10, Issue 16 IMP1 is a novel posttranscriptional regulator of early erythroid development and embryonic globin output August 25 2026 - Volume 10, Issue 16 Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds August 25 2026 - Volume 10, Issue 16 Bone mineral density, bone remodeling biomarkers, and hemostatic correlates in hemophilia and von Willebrand disease August 25 2026 - Volume 10, Issue 16 Delayed ADAMTS13 normalization in caplacizumab/PEX–treated patients associated with anti-ADAMTS13 IgG antibody boosting August 25 2026 - Volume 10, Issue 16 Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance) August 25 2026 - Volume 10, Issue 16 Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial August 25 2026 - Volume 10, Issue 16 Caution in interpreting prognostic genomic factors in underpowered subgroups of children with T-ALL August 25 2026 - Volume 10, Issue 16 Factors in the implementation of ASH SCD guidelines on silent cerebral infarcts and cognition at a single sickle cell center August 25 2026 - Volume 10, Issue 16 Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma August 25 2026 - Volume 10, Issue 16 ASH clinical practice guidelines: evaluation of discordance between certainty of evidence and strength of recommendations August 25 2026 - Volume 10, Issue 16 Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy August 25 2026 - Volume 10, Issue 16 Defining durability in SCD gene therapy August 25 2026 - Volume 10, Issue 16 Gene therapy for sickle cell disease durability August 25 2026 - Volume 10, Issue 16 Becker RC. Mechanism(s) of factor XI inhibition in clinical practice. Blood Advances. 2026;10(7):2538-2540. August 25 2026 - Volume 10, Issue 16 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer
New England Journal of Medicine, Volume 395, Issue 9, Page 882-893, September 3, 2026.
Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia New England Journal of Medicine, Volume 395, Issue 9, Page 845-858, September 3, 2026.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Volume 395, Issue 9, Page 870-881, September 3, 2026.
Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia New England Journal of Medicine, Volume 395, Issue 9, Page 859-869, September 3, 2026.
More on Causes of Death among Children and Adolescents in the United States New England Journal of Medicine, Volume 395, Issue 9, Page 934-936, September 3, 2026.
A Zoonotic Orthonairovirus from Febrile Patients in China New England Journal of Medicine, Volume 395, Issue 9, Page 929-931, September 3, 2026.
Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders New England Journal of Medicine, Volume 395, Issue 9, Page 926-929, September 3, 2026.
Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML New England Journal of Medicine, Volume 395, Issue 9, Page 917-919, September 3, 2026.
Fluid Resuscitation in Patients with Sepsis — For Whom the Balance Tolls New England Journal of Medicine, Volume 395, Issue 9, Page 921-922, September 3, 2026.
Scrofuloderma New England Journal of Medicine, Volume 395, Issue 9, Page 906-906, September 3, 2026.
Acro-Osteolysis New England Journal of Medicine, Volume 395, Issue 9, September 3, 2026.
Safe Space New England Journal of Medicine, Volume 395, Issue 9, Page 840-843, September 3, 2026.
Human–Animal Bonds as Social Determinants of Health Care Access New England Journal of Medicine, Volume 395, Issue 9, Page 838-840, September 3, 2026.
Pulmonary Nodules New England Journal of Medicine, Volume 395, Issue 9, Page 894-905, September 3, 2026.
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy New England Journal of Medicine, Ahead of Print.
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema New England Journal of Medicine, Ahead of Print.
Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment New England Journal of Medicine, Ahead of Print.
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism New England Journal of Medicine, Ahead of Print.
Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis New England Journal of Medicine, Ahead of Print.
Eplontersen for Transthyretin Amyloid Cardiomyopathy New England Journal of Medicine, Ahead of Print.
Tricuspid-Valve Intervention in Heart Failure New England Journal of Medicine, Ahead of Print.
Complete Revascularization Guided by Functional Coronary Angiography in STEMI New England Journal of Medicine, Ahead of Print.
Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients New England Journal of Medicine, Ahead of Print.
Prasugrel versus Ticagrelor in Acute Coronary Syndromes New England Journal of Medicine, Ahead of Print.
Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI New England Journal of Medicine, Ahead of Print.
Vasopressors or Fluids in Early Septic Shock New England Journal of Medicine, Ahead of Print.
Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease New England Journal of Medicine, Ahead of Print.
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
|
HopeFOL, or FOL of problems? Leucovorin for autistic symptoms
Volume 31, Issue 9, September 2026, oyag304 Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial Volume 31, Issue 9, September 2026, oyag250 Salvage treatment strategies for ipsilateral breast tumor recurrence after breast-conserving therapy: a real-world study Volume 31, Issue 9, September 2026, oyag274 Male breast cancer: from extrapolated practice to evidence-based care Volume 31, Issue 9, September 2026, oyag318 Lifestyle patterns and sleep disturbance among Black breast cancer survivors: results from the Women’s Circle of Health Follow-Up Study Volume 31, Issue 9, September 2026, oyag217 Targeted therapies in the management of advanced medullary thyroid cancer Volume 31, Issue 9, September 2026, oyag300 Empathy, access, and delays: determinants of oncology care satisfaction in Polish academic and nonacademic hospitals Volume 31, Issue 9, September 2026, oyag046 Use and overuse of positron emission tomography for patients with metastatic colorectal cancer Volume 31, Issue 9, September 2026, oyag336 Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers Volume 31, Issue 9, September 2026, oyag302 Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma Volume 31, Issue 9, September 2026, oyag317 Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer: unprecedented outcomes from KEYNOTE-B15 Volume 31, Issue 9, September 2026, oyag332 Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France Volume 31, Issue 9, September 2026, oyag316 Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review Volume 31, Issue 9, September 2026, oyag291 Chemical exposures as risk factors for the development of thyroid cancer Volume 31, Issue 9, September 2026, oyag299 Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis Volume 31, Issue 9, September 2026, oyag283 Optimizing postoperative prognostication in duodenal adenocarcinoma: a multicenter study with external validation Volume 31, Issue 9, September 2026, oyag261 Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers Volume 31, Issue 9, September 2026, oyag257 EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study) Volume 31, Issue 9, September 2026, oyag285 Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non–head-and-neck cutaneous squamous cell carcinoma Volume 31, Issue 9, September 2026, oyag252 A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting Volume 31, Issue 9, September 2026, oyag279 Molecular tumor board–guided osimertinib therapy in EGFR L858R/Q701L–mutant lung adenocarcinoma supported by functional validation Volume 31, Issue 9, September 2026, oyag242 The collapse of distance Volume 31, Issue 9, September 2026, oyag306 Watchful waiting in children with unifocal osseous Langerhans cell histiocytosis Volume 31, Issue 9, September 2026, oyag122 An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer Volume 31, Issue 9, September 2026, oyag327 Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025) Volume 31, Issue 9, September 2026, oyag296 Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue? Volume 31, Issue 9, September 2026, oyag293 Correction to: Rare occurrence of immunotherapy-related gastritis and duodenitis in a single tertiary medical center: a diagnostic challenge Volume 31, Issue 9, September 2026, oyag280 |
Being Artificially Intelligent September 2026: 69(9):2223-2225 How Much Does It Cost to Become a Colorectal Surgeon? A Cost Comparison of Training in the United States, Australia and New Zealand, and the United Kingdom September 2026: 69(9):2226-2229 Artificial Intelligence for Colorectal Surgeons—Part I: Foundations and Clinical and Educational Applications September 2026: 69(9):2230-2240 Herrmann and Desfosses, the 2 Men “Behind the Anal Glands”: A Brief Account of a Notable Page in the History of Proctology September 2026: 69(9):2241-2247 Managing Reach Limitations in Left-Sided Colectomy September 2026: 69(9):2248-2251 Expert Commentary on Managing Reach in Colectomy: Achieving a Tension-Free Anastomosis September 2026: 69(9):2252-2253 Oncologic Outcomes of Robot-Assisted Upfront Surgery Using a Fascia-Guided Total Mesorectal Excision Strategy for T3 Rectal Cancer September 2026: 69(9):2254-2265 Risk Factors for Small-Bowel Crohn’s Disease Recurrence After Total Proctocolectomy September 2026: 69(9):2266-2272 Sexual Distress Is Common in Long-term Follow-up After Pelvic Pouch for Ulcerative Colitis: A Cross-Sectional Study September 2026: 69(9):2273-2282 End-to-Side Ileocolonic Anastomosis After Ileocecectomy for Crohn’s Disease Is a Safe Option With Low Recurrence September 2026: 69(9):2283-2290 Quadratus Lumborum Block During Minimally Invasive Colorectal Surgery: A Tool for Enhanced Recovery September 2026: 69(9):2291-2300 Risk of Metabolic Disease After Right- Versus Left-Sided Colectomy for Colon Cancer: A Nationwide Cohort Study September 2026: 69(9):2301-2311 Cost-Effectiveness of Pelvic Floor Reconstruction Using Biological Mesh After Extralevator Abdominoperineal Resection for Rectal Cancer September 2026: 69(9):2312-2320 Patient-Level Socioecological Comorbidities and Time to Initiation of Curative-Intent Treatment for Colorectal Cancer September 2026: 69(9):2321-2331 Selected Abstracts September 2026: 69(9):2332-2336 Managing Reach Problems in Pouch Surgery: Lengthening Maneuvers and S-Pouch Creation September 2026: 69(9):2337-2337 Artificial Intelligence–Assisted Anatomical Recognition System-Guided Robotic Total Mesorectal Excision and Autonomic Nerve Preservation for Rectal Neuroendocrine Tumor September 2026: 69(9):2338-2338 Simultaneous Application of Robotic Surgery and Transanal Minimally Invasive Surgery Platform in the Context of Sphincter Preservation, Stepwise Description September 2026: 69(9):2339-2339 Robotic Lateral-to-Medial Left Colon Dissection: A Technical Approach for Total Mesorectal Excision September 2026: 69(9):2340-2342 Single-Port Robotic Transstomal End Colostomy Resection and Closure September 2026: 69(9):2343-2344 |
|
|
| |||
|
Biomarker Guides Treatment Sequencing, Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
Using a blood test to track thymidine kinase activity may help determine optimal first-line treatment for patients with BRAF V600–mutated metastatic melanoma, according to findings published in Clinical Cancer Research. Monday, August 31, 2026 12:00 PM High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer Adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC), according to results from the phase III SOLARIS trial led by Kimmie Ng, MD, MPH, and colleagues and... Additional Safety Analysis of DESTINY-Breast05: What Did It Show? An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios... FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia Today, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for essential thrombocythemia in nearly 3 decades. Ropeginterferon alfa-2b-njft has been... Monday, August 31, 2026 12:00 PM FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera On August 28, the U.S. Food and Drug Administration (FDA) approved rusfertide (Mimrylo) for the treatment of erythrocytosis in adults with polycythemia vera (PV). Rusfertide is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to... Monday, August 31, 2026 11:05 AM The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors According to findings from the prospective multicenter LAANTERN study reported by Leuthardt et al in the Journal of Clinical Oncology, laser interstitial thermal therapy (LITT) may offer a minimally invasive cytoreductive option for selected patients with primary and metastatic brain tumors, with... Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer A tissue-free circulating tumor DNA (ctDNA) assay was strongly prognostic for recurrence in patients treated for triple-negative breast cancer and provided a lead time to recurrence comparable to that of a multivariant tumor-informed assay, according to findings from a prognostic study published by ... Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some... Friday, August 28, 2026 10:00 AM In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. Friday, August 28, 2026 10:00 AM cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore. Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals AI is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, 2026, Cleveland Clinic in collaboration with the College of Healthcare Information Management Executives (CHIME), will host the Second ... Thursday, August 20, 2026 10:30 AM Cleveland Clinic President Discusses Friday’s AI Summit for Health-Care Professionals Artificial intelligence (AI) is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. Wednesday, August 26, 2026 3:41 PM ASTRO Updates Guideline on Radiation Therapy for Pancreatic Cancer An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer. The guideline updates ASTRO’s 2019 recommendations to reflect recent clinical trials that... Thursday, August 13, 2026 11:12 AM ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation WashU Medicine Appoints New Chief of Head and Neck Surgery Andrés M. Bur, MD, FACS, has been named Chief of the Division of Head and Neck Surgery in the Department of Otolaryngology–Head & Neck Surgery at WashU Medicine and Co-Director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish... Thursday, August 27, 2026 10:52 AM Colorectal Cancer May Cause Peripheral Neuropathy Before Treatment, Preclinical Study Finds Colorectal cancer may result in tumor-related inflammation that damages peripheral nerves before even starting cancer treatment, according to preclinical findings published in Nature Communications. This damage may be the reason why colorectal cancer survivors are more likely to develop peripheral... Wednesday, August 26, 2026 12:00 PM Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy Patients with acute myeloid leukemia (AML) frequently experienced unplanned hospital readmission or death within 30 days after discharge following induction chemotherapy, according to findings reported by Chae et al in JCO Clinical Cancer Informatics. The investigators found that incorporating... Prostate Cancer: NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA... Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82 FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including: Tuesday, August 25, 2026 1:00 PM ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma On August 26, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Wednesday, August 26, 2026 3:02 PM Research Finds Supercentenarians Have an Abundance of Cancer-Killing Immune Cells The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. These cells multiply in a process called clonal expansion to help fight infection. In a study published by Hashimoto in Cell Reports, researchers... Wednesday, August 26, 2026 11:47 AM Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study led by Amy L. Shaver, PhD, PharmD, MPH, and... Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study,... Monday, August 24, 2026 11:12 AM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
The development of diverse immunotherapeutic modalities has revolutionized the treatment of cancer but the effectiveness of these therapies remains restricted by fundamental mechanistic limitations relating to the generation of tumour-specific T cells, and their activation and/or access into the tumour microenvironment. In this Perspective, the authors position oncolytic viruses as a foundational immuno-oncology platform for systemic immune reprogramming to simultaneously overcome these availability, activation and admission barriers, and delineate four pillars for the development of a new generation of oncolytic virotherapies. Thu, 03 Sep 2026 00:00:00 -0700 Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC Thu, 27 Aug 2026 00:00:00 -0700 Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems The global cancer burden is projected to rise substantially in the coming decades, driven largely by population growth and ageing. Yet cancer patterns and outcomes vary widely across regions, reflecting differences in exposures, healthcare capacity and access to care. Translating these evolving epidemiological patterns into effective and equitable cancer-control strategies is increasingly urgent. Wed, 26 Aug 2026 00:00:00 -0700 Exploring the landscape of targetable alterations in patients with glioblastoma Despite considerable progress in other cancer types, progress with the development of targeted therapies for patients with glioblastoma has remained limited, despite considerable research effort. In this Review, the authors summarize the various attempts to develop effective targeted therapies for patients with glioblastoma, including some of the challenges that have likely impaired progress thus far. The authors also highlight novel therapies, clinical trial designs and research directions that have been informed by the shortcomings of previous research efforts, all of which might eventually lead to improved outcomes for patients. Wed, 19 Aug 2026 00:00:00 -0700 Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma The phase III FIGHT-302 trial demonstrated that the FGFR inhibitor pemigatinib improves progression-free survival and response rates versus first-line chemotherapy in patients with advanced-stage FGFR2-rearranged cholangiocarcinoma. However, the trial accrued slowly and closed early after chemoimmunotherapy became the new standard of care. FIGHT-302, alongside two similarly terminated trials, highlights the need for innovative trial designs and flexible regulatory frameworks to evaluate therapies in rare, biomarker-defined populations. Wed, 12 Aug 2026 00:00:00 -0700 How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease PROTEUS met its amended co-primary end points but should not be interpreted as practice changing. The trial compared two experimental strategies rather than the current standard of care, relied on an unvalidated approach (prostate-specific membrane antigen-PET) for assessments of metastasis-free survival, demonstrated minimal absolute benefit with increased toxicity and lacks both mature overall survival data and sufficient data on patient-reported outcomes to support adoption. Tue, 11 Aug 2026 00:00:00 -0700 The proteome comes of age, but precision oncology needs functional maps Yue and colleagues present a landmark anatomical atlas of human protein abundance across non-malignant tissues and cancers. We argue that precision oncology needs functional proteomic maps that add signalling activity, post-translational modifications, pathology-guided compartment resolution, metastatic and longitudinal sampling, clinical annotation and population diversity to make proteomics therapeutically actionable. Mon, 10 Aug 2026 00:00:00 -0700 HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL Fri, 07 Aug 2026 00:00:00 -0700 |
|
|
| |||
|
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Vol 17, No 4 (August 31, 2026): The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence Vol 17, No 4 (August 31, 2026): FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2 Vol 17, No 4 (August 31, 2026): Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study Vol 17, No 4 (August 31, 2026): Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study Vol 17, No 4 (August 31, 2026): Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study Vol 17, No 4 (August 31, 2026): Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study Vol 17, No 4 (August 31, 2026): Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma Vol 17, No 4 (August 31, 2026): Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway Vol 17, No 4 (August 31, 2026): The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study Vol 17, No 4 (August 31, 2026): Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM Vol 17, No 4 (August 31, 2026): Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer Vol 17, No 4 (August 31, 2026): Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study Vol 17, No 4 (August 31, 2026): Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with Hippo signaling pathway Vol 17, No 4 (August 31, 2026): Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer Vol 17, No 4 (August 31, 2026): Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis Vol 17, No 4 (August 31, 2026): Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression Vol 17, No 4 (August 31, 2026): A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators Vol 17, No 4 (August 31, 2026): Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study Vol 17, No 4 (August 31, 2026): Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study Vol 17, No 4 (August 31, 2026): Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression Vol 17, No 4 (August 31, 2026): Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis Vol 17, No 4 (August 31, 2026): Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer Vol 17, No 4 (August 31, 2026): Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study Vol 17, No 4 (August 31, 2026): Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 4 (August 31, 2026): Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study Vol 17, No 4 (August 31, 2026): Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study Vol 17, No 4 (August 31, 2026): A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Vol 17, No 4 (August 31, 2026): Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer Vol 17, No 4 (August 31, 2026): Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Vol 17, No 4 (August 31, 2026): Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study Vol 17, No 4 (August 31, 2026): Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations Vol 17, No 4 (August 31, 2026): Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis Vol 17, No 4 (August 31, 2026): Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior Vol 17, No 4 (August 31, 2026): Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial Vol 17, No 4 (August 31, 2026): Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy Vol 17, No 4 (August 31, 2026): Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection Vol 17, No 4 (August 31, 2026): Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial Vol 17, No 4 (August 31, 2026): Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries Vol 17, No 4 (August 31, 2026): Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database Vol 17, No 4 (August 31, 2026): Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection Vol 17, No 4 (August 31, 2026): Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications Vol 17, No 4 (August 31, 2026): Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis Vol 17, No 4 (August 31, 2026): Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study Vol 17, No 4 (August 31, 2026): A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study Vol 17, No 4 (August 31, 2026): SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023 Vol 17, No 4 (August 31, 2026): Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Vol 17, No 4 (August 31, 2026): Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review Vol 17, No 4 (August 31, 2026): MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review Vol 17, No 4 (August 31, 2026): Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review Vol 17, No 4 (August 31, 2026): From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer Vol 17, No 4 (August 31, 2026): Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial Vol 17, No 4 (August 31, 2026): Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features Vol 17, No 4 (August 31, 2026): Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts Vol 17, No 4 (August 31, 2026): Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility Vol 17, No 4 (August 31, 2026): Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prognostic role of resting heart rate in patients with colorectal cancer Vol 17, No 4 (August 31, 2026): DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation Vol 17, No 4 (August 31, 2026): Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? Vol 17, No 4 (August 31, 2026): Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold Vol 17, No 4 (August 31, 2026): Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting Vol 17, No 4 (August 31, 2026): Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash Vol 17, No 4 (August 31, 2026): Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors Vol 17, No 4 (August 31, 2026): Extending the utility of anti-EGFR therapy in metastatic colorectal cancer Vol 17, No 4 (August 31, 2026): Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity? Vol 17, No 4 (August 31, 2026): Ferroptosis in gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 4 (August 31, 2026): |
|
||
|
| |||
|
Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone
Annals of Internal Medicine, Volume 179, Issue 8, Page 1073-1084, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Prolonged Short Sleep and Its Effect on Body Weight and Composition Annals of Internal Medicine, Volume 179, Issue 8, Page 1085-1093, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Performance of Lung Cancer Risk Prediction Models in Different Racial and Ethnic Groups in the United States: Results From the Lung Cancer Cohort Consortium Annals of Internal Medicine, Volume 179, Issue 8, Page 1094-1106, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 8, Page 1107-1116, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis Annals of Internal Medicine, Volume 179, Issue 8, Page 1117-1127, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 8, Page 1128-1139, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 8, Page 1140-1155, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 8, Page 1156-1168, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Reporting Interest-Holder Engagement in Practice Guidelines: The RIGHT-MuSE Checklist Annals of Internal Medicine, Volume 179, Issue 8, Page 1169-1176, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026) Annals of Internal Medicine, Volume 179, Issue 8, Page 1177-1185, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Visual Guideline - Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Visual Clinical Guideline From the American College of Physicians (April 2026) Annals of Internal Medicine, Volume 179, Issue 8, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 How Would You Manage Perioperative Cardiovascular Risk for Noncardiac Surgery in This Patient With Complex Comorbidity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 8, Page 1186-1196, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Care of Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists Annals of Internal Medicine, Volume 179, Issue 8, Page 1197-1198, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Prior Authorization and Clinical Authority: Time to Recalibrate? Annals of Internal Medicine, Volume 179, Issue 8, Page 1199-1200, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Revitalizing Primary Care Internal Medicine: Addressing the Hidden Curriculum Annals of Internal Medicine, Volume 179, Issue 8, Page 1201-1202, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Treating Obesity With Pharmacotherapy: Making Sense of the Evolving Science When Data Are Vast but Direct Comparative Evidence Is Sparse Annals of Internal Medicine, Volume 179, Issue 8, Page 1203-1205, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Dear Resident Mother Annals of Internal Medicine, Volume 179, Issue 8, Page 1206-1207, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Giving Up Annals of Internal Medicine, Volume 179, Issue 8, Page 1208-1209, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Identifying Meaningful Patient Savings on Generics: Direct-to-Consumer Prices Versus Commercial Insurance Cost Sharing Annals of Internal Medicine, Volume 179, Issue 8, Page 1210-1212, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study Annals of Internal Medicine, Volume 179, Issue 8, Page 1212-1215, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1215-1216, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1216-1217, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1217-1217, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1217-1218, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1218-1218, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1218-1219, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall response rate and overall survival of 16 months.
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study The Phase 2 study was small and was not designed to establish the statistical difference between Vistagen’s drug candidate and placebo, according to Vistagen. The biotech plans to meet with the FDA to determine a registrational path for the asset.
BioVie shares halve on murky Parkinson’s disease readout BioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.
AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau candidates from Denali Therapeutics, Eisai and Eli Lilly.
ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress Theralase(R) Releases Q2 2026 Financial Statements Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026 FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial |
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BMO Capital Markets.
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful near-term milestones.
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
‘Worse than expected’ Wainua data muddies water for TTR silencers AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the standard of care for ATTR-CM, analysts say.
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion into chronic rhinosinusitis last year.
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis Applied Biologics Activates First Clinical Site in Phase 3 BIOxHEAL™ Trial Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation |
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BMO Capital Markets.
RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall response rate and overall survival of 16 months.
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful near-term milestones.
Breaking borders: Building biotech scale in Benelux In this episode of Denatured, you’ll hear from Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We explore why the Benelux region remains scientifically strong, but investment fragmented, and what it will take to turn it into a more unified biotech investment corridor.
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on understanding disease biology and selecting the right drug candidates to derisk clinical trials.
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.
ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS Ark Clinical Research Joins Genentech’s Advancing Inclusive Research® Site Alliance AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC |
|
|
| |||
|
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Fri, 04 Sep 2026 00:19:02 -0700
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:19:02 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:19:02 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:19:02 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:19:02 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:19:02 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:19:02 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:19:02 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:19:02 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:19:02 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:19:02 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:19:02 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:19:02 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:19:02 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:19:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:19:02 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:19:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:19:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:19:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:19:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:19:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:19:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:19:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:19:02 -0700
|
Amish lethal microcephaly: a new metabolic disorder with severe congenital microcephaly and 2-ketoglutaric aciduria.
Am J Med Genet. 2002 Nov 1;112(4):318-26. doi: 10.1002/ajmg.10529. Kelley RI, Robinson D, Puffenberger EG, Strauss KA, Morton DH The Evaluation of Molecular Genetics and Clinical Manifestations in Patients With LZTR1-Associated Noonan Syndrome: A Retrospective Chart Review and Review of Literature. Am J Med Genet A. 2026 Sep 2. doi: 10.1002/ajmg.a.70297. Jaouadi H, Hicazi Ş, Raski CR, Aschbacher-Smith L, Hijazi G, Roberts AE, Prada CE, Weaver KN Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders. N Engl J Med. 2026 Sep 3;395(9):926-929. doi: 10.1056/NEJMc2603114. Cheng YH, Shang K, Qin C, Dong MH, Chu YH, Huang K, Mei ZC, Xiao J, Liang ZH, Li YH, Wang W, Tian DS Adolescent health across Asia Pacific, 2000-23: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Child Adolesc Health. 2026 Oct;10(10):731-754. doi: 10.1016/S2352-4642(26)00163-X. GBD 2023 Asia Pacific Adolescent Health Collaborators Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia. N Engl J Med. 2026 Sep 3;395(9):845-858. doi: 10.1056/NEJMoa2602804. Fathi AT, Perl AE, Fell GG, Jonas BA, Ragon BK, Mims AS, Borate U, Mannis GN, Quillen K, Stahl M, Aubrey BJ, Koller P, Artz AS, Al Malki MM, Stein AS, Marcucci G, Peters MLB, Graubert TA, Westervelt P, Amrein PC, Hock HR, Brunner AM, Hobbs G, Narayan R, Lee MH, Miller PG, Watson AL, Hao R, Marola AC, Lombardi-Story J, Dhaver S, Grunwald MR, Chen YB, Weinstock MJ, Matthews AH, McGovern I, Wood BL, Hourigan CS, Neuberg DS, El-Jawahri A, Aldoss I Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026 Sep 2. doi: 10.1038/s41586-026-10940-7. Feng Y, Barthez M, Wang Y, Chen Y, Qiu H, Wang CL, Heydari K, Delcroix M, Rasmussen LJ, Bohr VA, Chen D Molecular mechanisms and pathogenesis of MASH. Nature. 2026 Sep;657(8130):59-75. doi: 10.1038/s41586-026-10529-0. Epub 2026 Sep 2. Gallage S, Govaere O, Anstee QM, Shulman GI, Tacke F, Heikenwalder M Sex-specific associations of the plasma-proteome with incident coronary artery disease. Cardiovasc Res. 2026 Sep 3:cvag186. doi: 10.1093/cvr/cvag186. Sier VQ, Dimitrova K, Peters EHAB, van der Loo WPM, Willems van Dijk K, van Heemst D, Bax WH, Quax PHA, Pasterkamp G, Mokry M, Jukema JW, Noordam R, de Vries MR Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy. Cancer Cell. 2026 Sep 1:S1535-6108(26)00384-3. doi: 10.1016/j.ccell.2026.08.007. Lin Z, Chandra M, Srinivas N, Ugurel S, Becker JC, Aran D Current therapeutic landscape and future treatment perspectives of MASH. Nature. 2026 Sep;657(8130):76-91. doi: 10.1038/s41586-026-10672-8. Epub 2026 Sep 2. Gallage S, Govaere O, Anstee QM, Shulman GI, Tacke F, Heikenwalder M Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Sep 3;395(9):882-893. doi: 10.1056/NEJMoa2504059. Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, Starodub A, Sommerhalder D, Hecht JR, Garrido-Laguna I, Barve M, Ou SI, Kar S, Bao L, Tao L, Vora R, Hegde A, Saltos A, Azad NS, Hong DS; RMC-6236-001 Investigators Biliary stricture management: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2026 Sep 3. doi: 10.1055/a-2921-6492. Lemmers A, Tringali A, Teles de Campos S, Vanella G, Liem KS, Arvanitakis M, Caillol F, Gerges C, Johnson G, Kylänpää L, Perez-Cuadrado Robles E, Petrone MC, Ramchandani M, van Hooft JE, Facciorusso A, Tham TC, Triantafyllou K Long-term adverse effects following COVID-19 vaccination: A comparative analysis of Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. Medicine (Baltimore). 2026 Aug 28;105(35):e50282. doi: 10.1097/MD.0000000000050282. Aldali JA, Meo SA Nut consumption in relation to all-cause and cause-specific mortality: a meta-analysis 18 prospective studies. Food Funct. 2017 Nov 15;8(11):3893-3905. doi: 10.1039/c7fo00915a. Chen GC, Zhang R, Martínez-González MA, Zhang ZL, Bonaccio M, van Dam RM, Qin LQ Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023. J Am Coll Cardiol. 2026 Aug 21:S0735-1097(26)07323-7. doi: 10.1016/j.jacc.2026.07.039. GBD 2023 Myocarditis Collaborators Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. Nutr Metab Cardiovasc Dis. 2014 Jun;24(6):639-47. doi: 10.1016/j.numecd.2013.12.014. Epub 2014 Jan 22. Tresserra-Rimbau A, Rimm EB, Medina-Remón A, Martínez-González MA, de la Torre R, Corella D, Salas-Salvadó J, Gómez-Gracia E, Lapetra J, Arós F, Fiol M, Ros E, Serra-Majem L, Pintó X, Saez GT, Basora J, Sorlí JV, Martínez JA, Vinyoles E, Ruiz-Gutiérrez V, Estruch R, Lamuela-Raventós RM; PREDIMED Study Investigators Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science. 2026 Sep 3;393(6815):eaec6116. doi: 10.1126/science.aec6116. Epub 2026 Sep 3. Heles M, Pasvolsky L, Sathishkumar H, Naara S, Vu Y, Stewart CL, Xie T, Gleber-Netto FO, McCarthy W, Yaniv D, Kamal SS, Elahi H, Zhu P, Uhelski ML, Chatwin J, Lara A, Stolley DL, Migden MR, Lee ZH, Thevasagayampillai S, Gunaratne PH, Ait-Ahmad K, Kuykendall MJ, Eksi SE, Cohen L, Borniger JC, Gottlieb E, Jones GH, Dougherty PM, Amit M Parental depression in offspring's internalization of stigma: A family-individual model of self-stigma. Am J Orthopsychiatry. 2026 Sep 3. doi: 10.1037/ort0000948. Du N, Huang YT 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026 Aug 28:ehag100. doi: 10.1093/eurheartj/ehag100. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, Brugts JJ, Chioncel O, Donal E, Ferdinandy P, Jhund PS, Leyva F, Lorusso R, Madigan M, Mullens W, Paolillo S, Ryan N, Simpson M, Thiele H, Thune JJ, Van Craenenbroeck EM, Van Laake LW, Verbakel M; ESC Guidelines Advisory Group Impacts of arginine nutrition on embryonic and fetal development in mammals. Amino Acids. 2013 Aug;45(2):241-56. doi: 10.1007/s00726-013-1515-z. Epub 2013 Jun 4. Wu G, Bazer FW, Satterfield MC, Li X, Wang X, Johnson GA, Burghardt RC, Dai Z, Wang J, Wu Z |
||